Jcr Pharmaceuticals Co., Ltd.
Clinical trials sponsored by Jcr Pharmaceuticals Co., Ltd., explained in plain language.
-
New hope for hunter syndrome: Brain-Targeting drug in final testing
Disease control OngoingThis Phase 3 study tests a new drug called JR-141 against the current standard treatment (idursulfase) in 86 people with Hunter syndrome (MPS II). The goal is to see if JR-141 can better reduce harmful substances in the brain and improve thinking skills. Participants can switch t…
Phase: PHASE3 • Sponsor: JCR Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Hunter syndrome drug JR-141 tested for Long-Term safety
Disease control ENROLLING_BY_INVITATIONThis study is an extension of a previous trial testing JR-141, a drug given weekly by IV, for people with Hunter syndrome (a rare genetic disorder). It aims to see if the drug remains safe and effective over a longer period. About 80 participants who completed the earlier study w…
Phase: PHASE3 • Sponsor: JCR Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC